U.S. Stock News

NasdaqGS:RIGL
NasdaqGS:RIGLBiotechs

Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...
OTCPK:PBAM
OTCPK:PBAMBanks

Private Bancorp of America PBAM Credit Quality Worsening Challenges Bullish Margin Narrative

Private Bancorp of America (PBAM) has wrapped up FY 2025 with fourth quarter revenue of US$29.9 million and basic EPS of US$1.75, alongside trailing twelve month revenue of US$119.2 million and EPS of US$7.09. Over recent periods, the company has seen quarterly revenue move from US$26.8 million in Q3 2024 to just over US$30.5 million in Q2 2025, with quarterly EPS ranging from about US$1.64 to US$1.83 over that span. This sets a clear earnings base for investors to work from. With a trailing...
NasdaqGS:IDCC
NasdaqGS:IDCCSoftware

Is It Too Late To Consider InterDigital (IDCC) After A 4x Three Year Surge?

If you are wondering whether InterDigital's share price still offers value at current levels, you are not alone. This article walks through what that price might imply about the stock. After a strong 81.7% return over the past year and a very large 3-year gain of about 4x, the stock has recently cooled, with a 0.1% 7-day slip, a 5.0% decline over 30 days, and a 5.4% fall year to date from a last close of US$308.76. Recent attention on InterDigital has been shaped by ongoing interest in...
NasdaqGS:JBHT
NasdaqGS:JBHTTransportation

JB Hunt (JBHT) Margin Improvement Supports Bullish Earnings Narratives Despite Modest Revenue Trends

J.B. Hunt Transport Services (JBHT) just wrapped up FY 2025 with fourth quarter revenue of US$3.1b and basic EPS of US$1.90, alongside net income of US$181.1m. The company has seen quarterly revenue move from US$3.1b in Q4 2024 to US$3.1b in Q4 2025, while basic EPS shifted from US$1.53 to US$1.90 over the same period. Trailing twelve month EPS stands at US$6.12 on revenue of US$12.0b. With net margin at 5.0% and slightly higher than last year, the focus this season is on how efficiently...
OTCPK:MPCB
OTCPK:MPCBBanks

Mountain Pacific Bancorp (MPCB) Earnings Growth And 33.9% Margin Reinforce Bullish Profitability Narrative

Mountain Pacific Bancorp (MPCB) just wrapped up FY 2025 with fourth quarter revenue of about US$10.0 million and net income of US$3.1 million, set against a trailing twelve month total of US$38.7 million in revenue and US$13.1 million in net income. The company has seen revenue move from US$28.7 million to US$38.7 million on a trailing basis, while trailing earnings growth of 67.1% and a net profit margin of 33.9% frame a results season in which profitability and efficiency are front and...
NYSE:SSB
NYSE:SSBBanks

Is SouthState Bank (SSB) Pricing Reflect Its Potential After Recent Regional Bank Volatility

If you are wondering whether SouthState Bank's share price reflects its true worth, you are not alone. This article walks through what the current market price might be implying about value. The stock last closed at US$98.43, with returns of 0.8% over the past week, 0.8% over the last month, 4.5% year to date and 1.2% over the past year, while the 3 year and 5 year returns sit at 37.1% and 40.1% respectively. Recent moves in U.S. regional bank shares have kept investor attention on balance...
NasdaqGS:CHYM
NasdaqGS:CHYMDiversified Financial

Chime Financial (CHYM) Is Down 6.1% After Slower Growth And Shift To In-House Payments Strategy

Recently, Chime Financial reported slowing growth and sequential declines in purchase volume, prompting investors to reassess the fintech’s competitive position and outlook. At the same time, Chime is pushing into higher-margin products, in-house payment processing, and AI-driven features to broaden its customer base and improve unit economics. We’ll now examine how Chime’s shift to its own payment processing platform could influence the company’s investment narrative and long-term...
NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

Does Analyst Optimism on Innovation and Global Expansion Reshape the Bull Case for LeMaitre Vascular (LMAT)?

In recent days, LeMaitre Vascular has been highlighted for its focus on innovation and international expansion in vascular surgery devices, while some observers point to its relatively small revenue base and elevated valuation multiples versus larger peers. An interesting angle is how renewed analyst confidence, centered on the company’s specialized product portfolio and global growth ambitions, contrasts with concerns about subscale operations and pricing power dependence. We’ll now examine...
NasdaqGS:CTAS
NasdaqGS:CTASCommercial Services

Is Wells Fargo’s Upgrade Reframing the Competitive Moat Story for Cintas (CTAS)?

In recent days, Wells Fargo upgraded its rating on Cintas to “Overweight,” signaling increased confidence in the company’s financial outlook and market position as a provider of corporate identity uniforms and related services. This shift in analyst stance highlights how Cintas’s outsourcing-focused business model and service breadth are influencing professional views on its longer-term prospects. Next, we’ll examine how Wells Fargo’s more positive view of Cintas’s market position may...
NYSE:NGVT
NYSE:NGVTChemicals

Assessing Ingevity (NGVT) Valuation After Strong Recent Share Price Performance

Why Ingevity stock is drawing attention now Ingevity (NGVT) has been catching investor attention after recent share price moves, with the stock closing at $66.17 and showing double digit total returns over the past year and past 3 months. See our latest analysis for Ingevity. Recent trading has been strong, with a 30 day share price return of 13.56% and a 90 day share price return of 21.82%. The 1 year total shareholder return of 40.19% contrasts with weaker 3 and 5 year total shareholder...
NasdaqCM:KOPN
NasdaqCM:KOPNSemiconductor

Assessing Kopin (KOPN) Valuation After DarkWAVE Module Milestone With Theon International

Kopin (KOPN) is back on investor radar after Theon International placed a US$1 million development order for the company’s DarkWAVE module, moving the micro display platform toward production readiness for international defense customers. See our latest analysis for Kopin. Theon’s order and Kopin’s January conference appearances have landed at a time when the 30 day share price return of 18.4% contrasts with a weaker 90 day share price return of 18.68%, while the 1 year total shareholder...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Marex Group (MRX) Is Up 6.1% After Analyst Upgrades Highlight Its Diversified Earnings Engine

In recent days, Marex Group has drawn increased attention as analysts have raised earnings estimates and reinforced positive ratings on the UK-based financial services platform that provides liquidity, market access, and infrastructure across energy, commodities, and financial markets. This shift in analyst coverage highlights how Marex’s diversified operations and history of profit generation are gaining recognition in a space where the company has previously been relatively...
NasdaqGS:FLNC
NasdaqGS:FLNCElectrical

Is It Too Late To Reconsider Fluence Energy (FLNC) After 1-Year 63.7% Share Price Jump

If you are wondering whether Fluence Energy at around US$25.50 offers good value, or if the recent excitement has pushed the price too far, this breakdown is for you. The stock has seen returns of 20.4% over 7 days, 19.7% over 30 days, 10.8% year to date, and 63.7% over 1 year. These moves have attracted investors who are considering growth potential and changes in risk. Recent news flow has focused on Fluence Energy as a key player in energy storage solutions, with ongoing attention on how...
NasdaqGS:DHC
NasdaqGS:DHCHealth Care REITs

Does AlerisLife Cash and Portfolio Shift Change The Bull Case For Diversified Healthcare Trust (DHC)?

Diversified Healthcare Trust recently declared a regular quarterly cash distribution of US$0.01 per share, payable on or about February 19, 2026, and received US$27.2 million from AlerisLife’s asset sale and wind-down, with a further US$3 million to US$7 million expected. Together with the completed transition of all former Five Star communities to seven new operators and extensive non-core property sales, these cash inflows highlight DHC’s efforts to reshape its senior housing portfolio and...
NYSE:LAD
NYSE:LADSpecialty Retail

Earnings Beat Amid High Leverage Might Change The Case For Investing In Lithia Motors (LAD)

Lithia Motors recently delivered a quarterly update showing revenue ahead of analyst forecasts, with management pointing to stronger same-store sales, earnings per share, and profitability gains driven by its ongoing execution focus. At the same time, concerns around lagging same-store sales over the past two years, thin gross margins, and a high net-debt-to-EBITDA ratio highlight that Lithia’s operational progress is occurring alongside meaningful balance sheet and competitive...
NasdaqGS:FIGR
NasdaqGS:FIGRConsumer Finance

Is Figure (FIGR) Quietly Rewriting Its Competitive Edge With Blockchain-Native Equity Trading?

In recent days, Figure Technology Solutions launched its On-Chain Public Equity Network (OPEN), a blockchain-based platform that enables companies to issue, trade, and settle real equity directly on the Provenance blockchain while bypassing traditional intermediaries. This move highlights Figure’s push to make tokenized real-world equity more accessible, including peer-to-peer share lending and direct transfers that aim to cut friction in conventional market infrastructure. With this...
NasdaqGS:FYBR
NasdaqGS:FYBRTelecom

Frontier Communications Parent (FYBR) Valuation Check As Price-To-Sales Premium Contrasts With DCF Discount

Frontier Communications Parent (FYBR) has attracted attention after recent share moves, with the stock last closing at $38.44. Investors are weighing this price against the company’s fundamentals and its recent return profile. See our latest analysis for Frontier Communications Parent. Putting the latest move into context, Frontier’s recent 1-day, 7-day and 90-day share price returns, alongside an 8.28% 1-year total shareholder return and 34.88% 3-year total shareholder return, point to...
NYSE:INVX
NYSE:INVXEnergy Services

The Bull Case For Innovex International (INVX) Could Change Following Upbeat Earnings Revisions And Momentum Score Upgrade

Recent analyst updates have pushed Innovex International’s earnings estimates higher, coinciding with the company receiving a Momentum Style Score of B and a Zacks Rank of #2 (Buy), highlighting growing optimism about its near-term prospects. This combination of upward earnings revisions and a strong momentum profile suggests that analyst sentiment is increasingly aligned with the company’s recent operational and market performance signals. With these positive earnings estimate revisions in...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

GH Research (GHRS) Is Up 9.1% After FDA Lifts Clinical Hold On GH001 Depression Drug

GH Research PLC recently reported that the U.S. Food and Drug Administration lifted the clinical hold on its GH001 investigational new drug application, allowing U.S. subject enrollment following Phase 2b data in treatment-resistant depression showing a 15.5-point placebo-adjusted MADRS score reduction by Day 8, high remission rates with infrequent dosing, brief psychoactive sessions, and no serious treatment-related adverse events. This combination of rapid symptom relief, minimal treatment...
NasdaqGS:CRNX
NasdaqGS:CRNXPharmaceuticals

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress

Crinetics Pharmaceuticals (CRNX) has been in focus after a Goldman Sachs analyst upgrade that followed positive Phase 2 data for atumelnant in congenital adrenal hyperplasia and encouraging early revenue from newly launched Palsonify. See our latest analysis for Crinetics Pharmaceuticals. The latest move in Crinetics shares, which closed at US$56.43, comes after a string of updates including the Palsonify launch, positive atumelnant data, and a US$350.1m follow on equity raise. The 30 day...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

Is It Too Late To Reassess GlobalFoundries (GFS) After Its Recent Share Price Recovery

If you are wondering whether GlobalFoundries is reasonably priced or offering value at its recent levels, this article will walk through what the numbers actually say. The share price last closed at US$41.53, with returns of 6.7% over the past week, 12.0% over the last 30 days, 12.6% year to date, and 1.5% over the past year, while the 3 year return stands at a 25.2% decline. Recent commentary around GlobalFoundries has focused on its role in the broader semiconductor supply chain and how...
NasdaqGS:KYIV
NasdaqGS:KYIVWireless Telecom

Kyivstar Group (NasdaqGS:KYIV) Valuation Check After Recent Share Price Pullback

Kyivstar Group (KYIV) shares have pulled back sharply over the past month, even as the company reports annual revenue of $1.086b and net income of $127.0m. That mix of pressure and profitability is what investors are weighing now. See our latest analysis for Kyivstar Group. Looking beyond the recent pullback, the 30 day share price return of 19.74% and year to date share price return of 8.67% compare with a 1 year total shareholder return of 18.94%. This points to earlier strength now giving...
NasdaqCM:ALTO
NasdaqCM:ALTOChemicals

Alto Ingredients And 2 Other Promising Penny Stocks To Watch

As the AI stock rally cools, major U.S. indexes have been wavering, reflecting a broader market uncertainty. For investors willing to explore beyond well-known stocks, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Despite being considered a somewhat outdated term, penny stocks remain relevant for those seeking affordable entry points with potential growth prospects and financial resilience.